5 Einträge gefunden

1. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

   1. Goldschmidt, Hartmut
   2. Mai, Elias K
   3. Bertsch, Uta
   4. Fenk, Roland
   5. Nievergall, Eva
   6. Tichy, Diana
   7. Besemer, Britta

   2022 - Forschungsinformationssystem des UKE
2. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

   1. Dimopoulos, Meletios
   2. Weisel, Katja
   3. Moreau, Philippe
   4. Anderson, Larry D
   5. White, Darrell
   6. San-Miguel, Jesus
   7. Sonneveld, Pieter

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

   1. Mai, Elias K
   2. Miah, Kaya
   3. Bertsch, Uta
   4. Dürig, Jan
   5. Scheid, Christof
   6. Weisel, Katja C
   7. Kunz, Christina

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Response-adapted lenalidomide maintenance in newly diagnosed myeloma:results from the phase III GMMG-MM5 trial

   1. Goldschmidt, Hartmut
   2. Mai, Elias K
   3. Dürig, Jan
   4. Scheid, Christof
   5. Weisel, Katja C
   6. Kunz, Christina
   7. Bertsch, Uta

   2020 - Forschungsinformationssystem des UKE
5. Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group

   1. Goede, Valentin
   2. Bahlo, Jasmin
   3. Chataline, Viktoria
   4. Eichhorst, Barbara
   5. Dürig, Jan
   6. Stilgenbauer, Stephan
   7. Kolb, Gerald

   2016 - Forschungsinformationssystem des UKE